AYTU - Company ID 0001385818
AYTU BIOPHARMA, INC trades as AYTU. In its fiscal 2026 annual report the company posted revenue of $57.57M, down 13.3% from the prior year and net income of -$14.30M. This page tracks AYTU BIOPHARMA, INC through 893 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years AYTU BIOPHARMA, INC's revenue grew from $3.22M to $57.57M, a compound annual growth rate of 37.8%. Net profit margin expanded from -698.7% to -24.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-04-02 |
| SCHEDULE 13G/A | - | 2026-02-17 |
| SCHEDULE 13G/A | - | 2026-02-13 |
| Quarterly report | 10-Q | 2026-02-03 |
| Major company event | 8-K | 2026-02-03 |
| Major company event | 8-K | 2026-01-20 |
The largest companies sharing AYTU BIOPHARMA, INC's SEC industry classification (pharmaceutical preparations).
AYTU BIOPHARMA, INC reported revenue of $57.57M for fiscal year 2026, a decrease of 13.3% year over year.
In its latest fiscal year AYTU BIOPHARMA, INC reported a net loss of $14.30M.